Summary
Data on coronavirus disease 2019 (COVID-19) prevalence in the Democratic Republic of Congo (DRC) are scarce. We conducted a cross-sectional study to determine the seroprevalence of antibodies against anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the slum of Kadutu, city of Bukavu, between June and September 2021. The survey participants were all unvaccinated against SARS-CoV-2. The crude seroprevalence rate was adjusted to the known characteristics of the assay. Participants aged 15 to 49 years old made up 80 % of the population enrolled in the study (n=507; 319 women and 188 men). The overall crude and adjusted seroprevalence rates of antibodies for COVID-19 were 59.7 % (95 % CI 55.4 % - 63.9 %) and 84.0 % (95 % CI 76.2 % to 92.4 %), respectively. This seroprevalence rate indicates widespread dissemination of SARS-CoV-2 in these communities. COVID-19 symptoms were either absent or mild in more than half of the participants with antibodies for COVID-19 and none of the participants with antibodies for COVID-19 required hospitalization. These results suggest that SARS-CoV-2 spread did not appear to be associated with severe symptoms in the population of these settlements and that many cases went unreported in these densely populated locations. The relevance of vaccination in these communities should be thoroughly investigated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Belgian Cooperation Agency of the ARES (Academie de Recherche et d Enseignement Superieur) [grant COOP-CONV-20-022]. The funder did not play any role in the study design, collection, analysis, and interpretation of data, manuscript writing, or the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Ethical Review Committee of the Universite Catholique de Bukavu (number UCB/CIES/NC/02312021). All participants or their guardians (in the case of children) provided written consent before enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Leonid M. Irenge: leonid.irenge{at}uclouvain.be
Homer M. Bulakali: homerbulakali{at}gmail.com
Jérôme Ambroise: jerome.ambroise{at}uclouvain.be
Arthur Irenge Akonkwa: arthurirenge{at}protonmail.com
Jean-Luc Gala*: jean-luc.gala{at}uclouvain.be
Data Availability
The databases used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
